Americans, regardless of their insurance status, can now access Sanofi’s most widely prescribed insulin for $35 through the prescription drug savings company GoodRx, the companies announced Thursday.
Patients with a valid prescription can specifically access a $35 coupon for Sanofi’s Lantus on GoodRx’s site and redeem it at more than 70,000 retail pharmacies across the U.S., including CVS, Walgreens and Walmart.
Those three companies, which control over 90% of the global insulin market, moved to slash prices after years of political pressure and public outrage over the high costs of diabetes care in the U.S. Americans pay roughly eight times more for insulin than other developed countries, making diabetes the country’s most expensive chronic condition.
Sanofi said in March that it would lower list prices for Lantus and cap out-of-pocket costs for people with insurance at $35 a month. But the change won’t be effective until January.
The French company also has an existing patient assistance program to cap insulin prices for uninsured diabetes patients at the same price. But some patients have struggled to access the $35 price point, even with that program in place.
That’s due to low awareness among patients about copay cards and patient savings programs that can assist with out-of-pocket costs. Health experts and patient advocates have raised concerns that those programs, which manufacturers run, often require people to jump through hoops just to save money.
Pharma companies spend more than $5 billion on marketing patient support programs every year, but only 3% of patients actually use them, according to a 2021 survey from Phreesia Life Sciences.
President Joe Biden’s Inflation Reduction Act also capped monthly insulin costs for Medicare beneficiaries at $35, but it did not provide protection to diabetes patients who have private insurance.
Roughly 37 million people in the U.S., or 11.3% of the country’s population, have diabetes, according to the Centers for Disease Control and Prevention. Approximately 8.4 million diabetes patients rely on insulin, the American Diabetes Association said.
Disclaimer
The information contained in South Florida Reporter is for general information purposes only.
The South Florida Reporter assumes no responsibility for errors or omissions in the contents of the Service.
In no event shall the South Florida Reporter be liable for any special, direct, indirect, consequential, or incidental damages or any damages whatsoever, whether in an action of contract, negligence or other tort, arising out of or in connection with the use of the Service or the contents of the Service. The Company reserves the right to make additions, deletions, or modifications to the contents of the Service at any time without prior notice.
The Company does not warrant that the Service is free of viruses or other harmful components
This article originally appeared here and was republished with permission.
